Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17;6(6):CD016052.
doi: 10.1002/14651858.CD016052.

Androgens for genitourinary and vasomotor symptoms associated with menopause

Lucia A Lara  1 , Denisse Cartagena-Ramos  2 , Debora Cantelli  1 , Carla M F Dias  1 , Sarah Armstrong  3 , Vanessa Jordan  4 , Miguel Fuentealba-Torres  5
Affiliations

Androgens for genitourinary and vasomotor symptoms associated with menopause

Lucia A Lara et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of androgens compared to placebo or no intervention, or another active treatment for genitourinary and vasomotor symptoms in perimenopausal or postmenopausal women.

PubMed Disclaimer

Conflict of interest statement

LA Lara has no commercial or non‐commercial conflicts of interest relevant to this review.

D Cartagena‐Ramos has no commercial or non‐commercial conflicts of interest relevant to this review.

D Canteli has no commercial or non‐commercial conflicts of interest relevant to this review.

MFC Dias has no commercial or non‐commercial conflicts of interest relevant to this review.

S Armstrong is an editor for the Cochrane Gynaecology and Fertilty group but has not been involved in the editorial process for this review.

V Jordan is a Sign‐off editor for Cochrane and an editor for the Cochrane Gynaecology and Fertilty group but has not been involved in the editorial process for this review.

M Fuenteallba‐Tores has no commercial or non‐commercial conflicts of interest relevant to this review.

References

    1. Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA 2023;329(5):405-20. [DOI: 10.1001/jama.2022.24140] - DOI - PubMed
    1. Nappi R, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Medical treatment of female sexual dysfunction. Urologic Clinics of North America 2022;49(2):299-307. [DOI: 10.1016/j.ucl.2022.02.001] - DOI - PubMed
    1. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management pptions. Journal of Clinical Endocrinology and Metabolism 2021;106(1):1-15. [DOI: 10.1210/clinem/dgaa764] [PMID: ] - DOI - PubMed
    1. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11(1):32-43. [DOI: ] [PMID: 10.1080/13697130701744696 ] - PubMed
    1. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology 2013;34(3):211-27. [DOI: 10.1016/j.yfrne.2013.07.003] [PMID: ] - DOI - PMC - PubMed

LinkOut - more resources